Skip to content

Bicara 制药

US · BCAX #3193 按市值排名 上市于 2024
16.78 -0.84 -4.77%
实时 - 追踪5344个代码 - 心跳于201秒前 · 2026-10-16 18:18

最新新闻

  • 评级变动
    Analysts Are Bullish on Top NA Stocks: Veradermics, Incorporated (MANE), Bicara Therapeutics Inc. (BCAX)
    TipRanks · 2026/8/12
  • 评级变动
    Morgan Stanley Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $37
    \u5e02\u573a\u8d44\u8baf · 2026/8/12
  • Analysts Conflicted on These NA Names: Bicara Therapeutics Inc. (BCAX), CoreWeave (CRWV) and Cardinal Infrastructure Group, Inc. (CDNL)
    TipRanks · 2026/8/12
  • 评级变动
    BofA Securities Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Announces Target Price $34
    \u5e02\u573a\u8d44\u8baf · 2026/8/12
  • 评级变动
    BTIG Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Raises Target Price to $39
    \u5e02\u573a\u8d44\u8baf · 2026/8/12
  • 评级变动
    Bicara Therapeutics Inc. (BCAX) Gets a Hold From Wells Fargo
    TipRanks · 2026/6/2
  • Mizuho Securities Reaffirms Their Hold Rating on Bicara Therapeutics Inc. (BCAX)
    TipRanks · 2026/8/13
  • 评级变动
    BofA Securities Maintains Bicara Therapeutics(BCAX.US) With Buy Rating
    \u5e02\u573a\u8d44\u8baf · 2026/6/2
  • 评级变动
    Analysts Offer Insights on NA Companies: Enhanced Group (ENHA), MNTN, Inc Class A (MNTN) and Bicara Therapeutics Inc. (BCAX)
    TipRanks · 2026/8/12
  • 评级变动
    Wedbush Reaffirms Their Buy Rating on Bicara Therapeutics Inc. (BCAX)
    TipRanks · 2026/8/13
  • 评级变动
    Goldman Sachs Keeps Their Hold Rating on Bicara Therapeutics Inc. (BCAX)
    TipRanks · 2026/6/2
  • 评级变动
    Analysts' Top Healthcare Picks: Vertex Pharmaceuticals (VRTX), Bicara Therapeutics Inc. (BCAX)
    TipRanks · 2026/6/2
  • BMO Capital Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $35
    \u5e02\u573a\u8d44\u8baf · 2026/10/7
  • 评级变动
    Analysts Have Conflicting Sentiments on These NA Companies: Bending Spoons (BSP), EToro (ETOR) and Bicara Therapeutics Inc. (BCAX)
    TipRanks · 2026/8/12
  • Stifel Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Cuts Target Price to $45
    \u5e02\u573a\u8d44\u8baf · 2026/8/14
  • 评级变动
    BTIG Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $28
    \u5e02\u573a\u8d44\u8baf · 2026/7/28
  • 评级变动
    Wedbush Remains a Buy on Bicara Therapeutics Inc. (BCAX)
    TipRanks · 2026/5/27
  • 评级变动
    H.C. Wainwright Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $42
    \u5e02\u573a\u8d44\u8baf · 2026/6/1
  • 评级变动
    Analysts Offer Insights on NA Companies: Smithfield Foods (SFD), Bicara Therapeutics Inc. (BCAX) and Concentra Group Holdings Parent, Inc. (CON)
    TipRanks · 2026/8/12
  • JonesTrading Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $30
    \u5e02\u573a\u8d44\u8baf · 2026/9/8

新闻标题为自动聚合内容,未经我们团队独立核实或编辑。

报价时间 2026-10-16 18:18:37 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

Bicara 制药 讨论区 0 条评论

发表评论